Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

Fusion Imaging Studied for Prostate Cancer

Facebook Twitter LinkedIn Email Comments
PRINCETON, N.J., April 30 -- Combining prostate cancer images with dual-modality imaging, or fusion imaging, can help detect the location and extent of prostate cancer, said researchers at University Hospitals of Cleveland, Case Western Reserve University, who will present findings at the American Urological Association's annual meeting today in Chicago.

The researchers will discuss their studies of 400 prostate cancer patients whose treatment was significantly modified by fused ProstaScint and CT imaging, said D. Bruce Sodee, M.D., professor of radiology at the university.

ProstaScint, an antibody-based imaging agent used to reveal the extent and spread of prostate cancer, is manufactured by Cytogen Corp., a biopharmaceutical company that focuses on oncology.

"The studies illustrate that ProstaScint fusion imaging and optimization can be used to guide both surgery and radiation therapy in addition to following the progress of patients' disease," said Martin I. Resnick, M.D., chief of urology at Case Western and president-elect of the American Urological Association.

For more information, visit:
Apr 2003
American Urological Associationcomputed tomographydual-modality imagingenergyfusion imagingNews & FeaturesProstaScintprostate cancer

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.